Redefining Tomorrow’s Therapies! Register NOW!

Redefining Tomorrow’s Therapies

We will bring together leading voices from academia and industry to explore transformative approaches that are redefining how we develop and deliver therapies for the future. The session will be expertly chaired by Dr. Han-Chung Wu, Director of the Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan.

The discussion begins with Eric Huang, Partner at Delos Capital, who will examine the arrival of N-of-1 gene editing, sharing critical insights into the challenges and opportunities of preparing these highly personalized therapies for large-scale implementation.

Following this, Boon Tong Koh, Executive Director of the Bioprocessing Technology Institute (BTI) and Chief Industry Officer at the Biomedical Research Council (BMRC) under A*STAR, will share Singapore’s strategic advancements in mRNA manufacturing, highlighting the region’s growing role in global bioprocessing capacity.

As the field of antibody drug conjugates (ADCs and RDCs) continues to evolve, Sherry Ku, President of Kuder Consulting Company, will provide a comprehensive overview of the latest innovations and scientific progress driving this promising class of targeted therapies.

Adding a clinical perspective, Christine Marie Dela Cruz, Director of Medical Affairs in Oncology and Hematology at ICON Biotech, will offer valuable insights into the medical considerations involved in bringing ADC therapies into cancer clinics and improving patient outcomes.

Be part of this exciting journey into the future of medicine at BIO Asia–Taiwan 2025.

Early Bird: Register by 6/20 & Save $275

www.bioasiataiwan.com

+886-2-27836028

BIO Asia–Taiwan 2025 Secretariat

BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會